Trials / Completed
CompletedNCT02268409
Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004)
An Open-Label Extension Study To Evaluate The Long-Term Effects Of ACE-536 In Patients With β-Thalassemia Previously Enrolled In Study A536-04
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study A536-06 (MK-6143-004) is an open-label extension study for participants previously enrolled in study A536-04 (NCT01749540), to evaluate the long-term safety and tolerability of luspatercept in adult participants with beta-thalassemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | luspatercept | subcutaneous injection |
Timeline
- Start date
- 2014-10-20
- Primary completion
- 2020-06-18
- Completion
- 2020-06-18
- First posted
- 2014-10-20
- Last updated
- 2024-07-18
- Results posted
- 2024-07-18
Locations
7 sites across 2 countries: Greece, Italy
Source: ClinicalTrials.gov record NCT02268409. Inclusion in this directory is not an endorsement.